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A B S T R A C T Leukemic cells from 70% of patients with Ia+CALLA+ non-T cell acute lymphoblastic leukemia (ALL) express an antigen (Bi) found on all normal B lymphocytes. In this study, ALL cells that do not express the Bi antigen were studied in an attempt to further elucidate the cellular lineage of these tumors. Non-T cell ALL lines and tumor cells isolated from patients with non-T cell ALL that are Ia+CALLA+Bl-were studied in vitro with a variety of agents known to promote cellular differentiation. Phorbol diester (TPA) or phytohemagglutinin conditioned leukocyte culture media were capable of inducing the expression of Bl on all four non-T cell ALL lines tested. In contrast, Bl could not be induced under the identical conditions on a promyelocytic leukemia line or a T cell lymphoblastic leukemia line. With the induction of Bl on non-T cell ALL lines, cytoplasmic u-heavy chain (cg) became undetectable, whereas the expression of CALLA and la were unchanged. The expression of BI was accompanied by a decrease of cellular proliferation and DNA synthesis, but no significant morphologic changes were noted. In addition, no other B or T cell antigens were detected.
The cellular origin of non-T cell ALL was further investigated using tumor cells isolated from leukemic patients. Tumor cells from eight patients with Ia+CALLA+Bl-c,-ALL could be induced in vitro with TPA to express both Bl and cy. In contrast, cells from five patients with Ia+CALLA-B1-cM-non-T cell ALL could not be induced with TPA to express CALLA, Bl, or cq. These studies suggest that the non-T cell ALL are heterogeneous and represent a spectrum of early B cell differentiation including the prepre-B cell (Ia+CALLA+Bl-cu-), the intermediate pre-B cell (Ia+CALLA+Bl+cu-), and finally the "true" pre-B cell (Ia+CALLA+Bl+c,+). The cellular
INTRODUCTION
Leukemic cells from '-80% of patients with acute lymphoblastic leukemia (ALL)' lack both cell surface immunoglobulin and T cell antigens. Although these cells are devoid of conventional B or T cell antigens, they express a variety of cell surface markers including the common acute lymphoblastic leukemia antigen (CALLA) (1) (2) (3) (4) (5) and the Ia-like antigens (Ia) (6, 7) . The cellular origin of these non-T ALL has been the subject of numerous studies that, for the most part, suggest that they are of B cell origin. Several laboratories have demonstrated that tumor cells from -20-30% of patients with non-T ALL have a pre-B cell phenotype since they express intracytoplasmic u-chain but lack cell surface immunoglobulin (8) (9) (10) . In addition, non-T cell ALL cells express B cell surface markers other than immunoglobulins (11) (12) (13) .
In a recent study, we described a monoclonal antibody, termed anti-Bl, which identifies a unique B cell surface differentiation antigen present on all normal B lymphocytes (13, 14) . This antibody was also reactive with all B cell lymphomas and B cell chronic lymphocytic leukemias (CLL) expressing monoclonal surface k or X light chains (13) . In addition, tumor cells from -50% of non-T ALL were reactive with anti-Bl suggesting a B cell lineage of these tumors.
Thus, the non-T ALL could be divided into the following groups: (a) Ia+CALLA+Bl+ (50%) (b) Ia+CALLA+Bl-(30%); and (c) Ia+CALLA-Bi-(20%).
In the present study, non-T cell ALL lines and tumor cells from patients with non-T cell ALL that were not reactive with anti-BI antibody (Ia+CALLA+Bl-) were studied in vitro with a variety of agents known to promote cellular differentiation. The studies to be described below demonstrate that both phorbol diester (TPA) and phytohemagglutinin conditioned leukocyte media (PHA-LCM) can induce the expression of the B1 antigen on CALLA+Ia+Bl-non-T cell leukemic lines. In addition, tumor cells from eight of nine patients with Ia+CALLA+Bl-non-T ALL can also be induced to express Bi. These studies support the view that the majority of Ia+CALLA+ non-T cell ALL are of B cell lineage.
METHODS
Cell lines. Cell lines Laz 221 (15) , 2072 , and 6972 were derived from patients with non-T cell ALL. The NALM-1 cell line was derived from a patient with lymphoid blast crisis of chronic myelocytic leukemias (16) . The HL-60 cell line was developed from a patient with promyelocytic leukemia (17) and the CEM cell line was developed from a patient with a T cell lymphoblastic lymphoma (18) . Laz (19) . Heparinized peripheral blood or bone marrow was collected from leukemic patients before the administration of chemotherapeutic agents or blood products. Mononuclear cells were separated from these specimens by Ficoll-Hypaque density centrifugation as previously described (20) . Tumor (23) . In addition, affinity purified directly fluoresceinated rabbit anti-human ,u and y antibodies were also used (Dako Immunoglobulins, Accurate Chemical Co., CA). Monoclonal anti-Bl has previously been shown to be specific for normal B cells with the exception of terminally differentiated plasma cells and is also reactive with malignant cells of B lineage (13, 14, 23) . Monoclonal anti-B2 defines a B cell-specific antigen that has a more limited expression than Bi and is found on normal and malignant B lymphocytes that express surface immunoglobulins that have not undergone "transformation" (24) . The CALLA antigen is defined by the J5 monoclonal antibody that defines a 100,000-mol wt glycoprotein expressed on the leukemic cells of 80% of patients with non-T cell ALL and 30-50% of patients with chronic myelocytic leukemia in blast crisis (1) (2) (3) (4) (5) (6) . A small number of normal bone marrow cells and fetal liver cells also express CALLA. It has been recently shown that CALLA is also found on '40% of patients with T cell lymphoblastic lymphoma and most patients with Burkitt's lymphoma, and on nodular poorly differentiated lymphocytic lymphoma (25) . The T cell surface antigens (T3, T4, T5/8, and T6) are defined by a series of monoclonal antibodies previously described in detail (26, 27) .
Indirect immunofluorescence
In brief, 1-2 X 106 cells were treated with either 0.1 ml of a 1:500 dilution of the specific monoclonal antibody to be tested or 0.1 ml of a 1:500 dilution of an unreactive control antibody of a similar isotype, incubated at 4°C for 30 min, and washed three times. These cells were then reacted with 0.1 ml of a 1:40 dilution of fluorescein conjugated goat antimouse IgG (G/M-FITC) (Meloy Laboratories, Springfield, VA), incubated at 4°C for 30 min, washed three times, and analyzed as previously described (28) . Intensity of fluorescence was determined for 10 DMSO (0.5-5%) and Ara-C (10 mM-10 nM) were also tested for their capacity to induce B cell antigens since these agents have been shown to promote cellular differentiation. Neither had an effect on the appearance of Bi, other B cell antigens, or T cell antigens.
Additional experiments were undertaken to investigate whether the Bi antigen could be induced on cell (Fig. 3, middle panel) (Table  V ). An example of TPA-induced Bi expression is shown in Fig. 4 (patient 3 
DISCUSSION
In several recent reports, we have described the preparation and characterization of a monoclonal antibody (anti-Bl), which is reactive with a novel differentiation antigen expressed on human B cells and on those cells destined to differentiate into immunoglobulin secreting cells following pokeweed mitogen stimulation (13, 14, (22) (23) (24) . The Bi antigen is expressed on surface immunoglobulin positive B lymphocytes isolated from peripheral blood and lymphoid organs and is not found on resting or activated T cells, monocytes, null cells, granulocytes, erythrocytes, or platelets. In lymphoid tissues, the Bi antigen is primarily localized in the lymphoid follicles, i.e. B cell regions (31) . When surface immunoglobulin-bearing B cells are stimulated with pokeweed mitogen, the Bi antigen is lost from the cell surface. The loss of Bi is accompanied by the development of presecretory cytoplasmic IgG and the appearance of plasma cells suggesting that Bi is a "pan-B cell" differentiation antigen (23) . Additional (31) 72 evidence that Bl is a "pan-B cell" differentiation antigen was derived from examination of the human B cell malignancies that encompass the entire spectrum of B cell differentiation (13) . The Bi antigen is present on the cell surface of tumor cells isolated from over 100 patients with B cell non-Hodgkin's lymphoma and 100 patients with B cell CLL. In addition, the Bi antigen was absent from cells isolated from patients with multiple myeloma confirming the evidence that the Bi antigen is lost from the terminally differentiated B lymphocyte. In contrast to the expression of Bi on all surface immunoglobulin bearing B cells, the identification of the earliest B cell that expresses the Bi antigen has been more difficult. Since leukemias and lymphomas are thought to represent "relatively" fixed stages of normal differentiation, they may provide an important model for the study of normal hematopoietic differentiation (32) . Moreover, tumor cells have been induced by a variety of promoters of differentiation to progress along normal differentiative pathways (33, 34) . Presumably the genetic commitment towards a specific differentiation pathway has already been established in these cells and the inducing agents may merely induce a transcriptional event. In previous studies, we showed that approximately half of the non- Our studies also demonstrated that tumor cells isolated from patients with Ia+CALLA+Bl-non-T ALL could also be induced to express BL with TPA (Table  V) . Although three of the four non-T cell ALL cell lines were cytoplasmic ts positive (Table I) Over the last several years, a large number of studies have investigated the cellular origin of non-T cell ALL. Initially, these tumor cells were shown to express Ialike antigens providing the first evidence that these cells might be of B cell origin (7) . Subsequently, it was demonstrated that 80% of Ia+ and non-T cell ALL expressed the CALLA antigen (1) (2) (3) (4) (5) (6) . Recent studies have shown that CALLA is expressed on a small population of normal bone marrow cells (0-1%), regenerating bone marrow (1-3%) and on fetal liver cells (5-10%). These observations have led to the view that CALLA is an early B cell-associated antigen. The presence of CALLA on some T cell lymphomas, mature B lymphomas, and a related antigen in the kidney suggests that CALLA is more widely distributed (25, 38) . Definitive evidence that a subgroup of non-T cell ALL were of B cell origin came from the observation that tumor cells isolated from 20% of patients with Ia+CALLA+ non-T cell ALL contained cytoplasmic iu-heavy chains (8) (9) (10) . Other investigators have observed that some pre-B cell ALL express a phenotype that is "more differentiated" than the cytoplasmic ,i positive ALL (39) . They demonstrated that this subgroup of pre-B cell ALL have undergone cytoplasmic immunoglobulin isotype switching and/or light chain production (39) . Moreover, the recent studies of Korsmeyer et al. (40) demonstrating immunoglobulin gene rearrangements in several patients with non-T cell ALL provide additional evidence for the notion that non-T cell ALL are of pre-B or pre-pre-B cell origin.
Our observation that the Bi antigen was expressed on 50% of non-T cell ALL and on 70% of CALLA positive non-T cell ALL extended the number of non-T cell ALL that were thought to be of B cell lineage (13) . The present study demonstrated that almost all Ia+CALLA+Bl-M-non-T ALL could be induced to express BL and cytoplasmic ,u suggesting that most if not all CALLA positive ALL are of B cell lineage. We, therefore, believe that the non-T cell ALL represent a spectrum of early B cell development from the prepre B cell (Ia+CALLA+Bl-M-), to the intermediate pre-B cell (Ia+CALLA+B1+,u-), and finally to the "true" pre-B cell (Ia+CALLA+Bl+u+). The cellular origin of ALL that express Ia+ but lack CALLA and BL is presently unknown. These observations may provide a framework for studies of normal early B cell differentiation.
